Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia
There is herein provided a compound of formula (I).
1. A pharmaceutical composition comprising (R)-2-(tert-Butylamino)-1-(3-fluorophenyl)ethan-1-ol, having the structure:
or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable adjuvant, diluent and/or carrier; wherein the (R)-2-(tert-Butylamino)-1-(3-fluorophenyl)ethan-1-ol is present in an enanteromeric excess of at least 90%.
2. A method of treating hyperglycaemia or a disorder characterized by hyperglycaemia comprising administering to a patient in need thereof a therapeutically effective amount of a compound as defined in claim 1 , or a pharmaceutically acceptable salt thereof.
3. The method according to claim 2 , wherein the hyperglycaemia or a disorder characterized by hyperglycaemia is type 2 diabetes.
4. The method according to claim 2 , wherein the patient displays severe insulin resistance.
5. The method according to claim 2 , wherein the disorder characterised by hyperglycaemia is selected from the group consisting of Rabson-Mendenhall syndrome, Donohue's syndrome (leprechaunism), Type A and Type B syndromes of insulin resistance, the HAIR-AN (hyperandrogenism, insulin resistance, and acanthosis nigricans ) syndromes, pseudoacromegaly, and lipodystrophy.